Kelly Davis Orcutt
Overview
Explore the profile of Kelly Davis Orcutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilcoxen K, Hesterman J, Orcutt K, Hoppin J
Per Med
. 2018 May;
8(4):469-481.
PMID: 29783339
The pharmaceutical and healthcare industries are being revolutionized by the use of genomics, proteomics, metabolomics, bioinformatics and molecular imaging. Patient friendly diagnosis, treatment and disease management options that utilize the...
2.
Yazaki P, Lee B, Channappa D, Cheung C, Crow D, Chea J, et al.
Protein Eng Des Sel
. 2012 Nov;
26(3):187-93.
PMID: 23175797
A series of anti-tumor/anti-chelate bispecific antibody formats were developed for pre-targeted radioimmunotherapy. Based on the anti-carcinoembryonic antigen humanized hT84.66-M5A monoclonal antibody and the anti-DOTA C8.2.5 scFv antibody fragment, this cognate...
3.
Orcutt K, Rhoden J, Ruiz-Yi B, Frangioni J, Wittrup K
Mol Cancer Ther
. 2012 Apr;
11(6):1365-72.
PMID: 22491799
Small-molecule ligands specific for tumor-associated surface receptors have wide applications in cancer diagnosis and therapy. Achieving high-affinity binding to the desired target is important for improving detection limits and for...
4.
Hoppin J, Orcutt K, Hesterman J, Silva M, Cheng D, Lackas C, et al.
J Pharmacol Exp Ther
. 2011 Feb;
337(2):350-8.
PMID: 21317355
Recent advances in small-animal molecular imaging instrumentation combined with well characterized antibody-labeling chemistry have enabled detailed in vivo measurements of antibody distribution in mouse models. This article reviews the strengths...
5.
Orcutt K, Slusarczyk A, Cieslewicz M, Ruiz-Yi B, Bhushan K, Frangioni J, et al.
Nucl Med Biol
. 2011 Feb;
38(2):223-33.
PMID: 21315278
Introduction: In pretargeted radioimmunotherapy (PRIT), a bifunctional antibody is administered and allowed to pre-localize to tumor cells. Subsequently, a chelated radionuclide is administered and captured by cell-bound antibody while unbound...
6.
Orcutt K, Nasr K, Whitehead D, Frangioni J, Wittrup K
Mol Imaging Biol
. 2010 Jun;
13(2):215-21.
PMID: 20533093
Purpose: The favorable pharmacokinetics and clinical safety profile of metal-chelated 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) suggests that it might be an ideal hapten for pretargeted radioimmunotherapy. In an effort to minimize hapten...
7.
Orcutt K, Ackerman M, Cieslewicz M, Quiroz E, Slusarczyk A, Frangioni J, et al.
Protein Eng Des Sel
. 2009 Dec;
23(4):221-8.
PMID: 20019028
Here we present a bispecific antibody (bsAb) format in which a disulfide-stabilized scFv is fused to the C-terminus of the light chain of an IgG to create an IgG-scFv bifunctional...
8.
Ackerman M, Levary D, Tobon G, Hackel B, Orcutt K, Wittrup K
Biotechnol Prog
. 2009 Apr;
25(3):774-83.
PMID: 19363813
Protein engineering relies on the selective capture of members of a protein library with desired properties. Yeast surface display technology routinely enables as much as million-fold improvements in binding affinity...